Consistent with the role of MYC, CHK1 and BRD4 in promoting aggressive HCC, higher‐grade tumors were observed in patients with high expression of all three targets as opposed to those with low expression levels (55.56% vs. 18.00%) (Figure 4dii,iii). The gene discussed is MYC; the disease is hepatocellular carcinoma.